Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Cerilliant
Queensland Health
QuintilesIMS
Moodys
Cipla
Novartis
Healthtrust
Medtronic
McKinsey

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,652,527

« Back to Dashboard

Which drugs does patent 8,652,527 protect, and when does it expire?

Patent 8,652,527 protects QUDEXY XR and is included in one NDA.

This patent has seven patent family members in five countries.
Summary for Patent: 8,652,527
Title:Extended-release topiramate capsules
Abstract: An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).
Inventor(s): Betterman; Sarah Michelle (Champlin, MN), Tantry; Jaidev Srinvas (Maple Grove, MN), Patrick; Laura Marie (Eden Prairie, MN)
Assignee: Upsher-Smith Laboratories, Inc (Maple Grove, MN)
Application Number:13/847,042
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Drugs Protected by US Patent 8,652,527

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Upsher-smith Labs QUDEXY XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 205122-001 Mar 11, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Upsher-smith Labs QUDEXY XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 205122-002 Mar 11, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Upsher-smith Labs QUDEXY XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 205122-003 Mar 11, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Upsher-smith Labs QUDEXY XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 205122-004 Mar 11, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Upsher-smith Labs QUDEXY XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 205122-005 Mar 11, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,652,527

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,889,190 Extended-release topiramate capsules ➤ Sign Up
9,101,545 Extended-release topiramate capsules ➤ Sign Up
9,555,005 Extended-release topiramate capsules ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,652,527

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2905011 ➤ Sign Up
European Patent Office 2968177 ➤ Sign Up
Israel 241053 ➤ Sign Up
South Korea 101674509 ➤ Sign Up
South Korea 20150132838 ➤ Sign Up
South Korea 20160124930 ➤ Sign Up
World Intellectual Property Organization (WIPO) 2014143380 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Federal Trade Commission
Mallinckrodt
Fish and Richardson
Teva
Cipla
Queensland Health
McKesson
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot